Cala Health, Inc.
9
0
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
67%
4 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Long-Term Transcutaneous Stimulation and Essential Tremor: A PET Study
Role: collaborator
RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor
Role: lead
Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor
Role: lead
Prospective Study for Symptomatic Relief of ET With Cala Therapy
Role: lead
Cala ONE Device for Essential Tremor
Role: lead
Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis
Role: lead
Peripheral Nerve Stimulation Therapy for Atrial Fibrillation
Role: lead
Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands
Role: lead
A Pilot Study of the Cala ONE Device for Essential Tremor
Role: lead
All 9 trials loaded